[{"id":"89c75df9-9804-4899-a467-168d5893aeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316116","created_at":"2022-04-07T13:56:37.378Z","updated_at":"2025-02-25T17:01:47.416Z","phase":"Phase 1","brief_title":"Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)","source_id_and_acronym":"NCT05316116","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sylvant (siltuximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 11/17/2026","primary_completion_date":" 11/17/2026","study_txt":" Completion: 11/17/2027","study_completion_date":" 11/17/2027","last_update_posted":"2025-02-03"},{"id":"21b0c328-ef65-489f-97f4-6f64457182a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03315026","created_at":"2021-01-18T16:22:17.873Z","updated_at":"2024-07-02T16:35:30.682Z","phase":"Phase 2","brief_title":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","source_id_and_acronym":"NCT03315026","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sylvant (siltuximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-11-02"},{"id":"819ddf6a-92fd-4e69-a9c7-80cd6ae4f183","acronym":"SILTUXILAM","url":"https://clinicaltrials.gov/study/NCT05697510","created_at":"2023-01-26T16:02:10.196Z","updated_at":"2024-07-02T16:35:51.296Z","phase":"Phase 1","brief_title":"Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM","source_id_and_acronym":"NCT05697510 - SILTUXILAM","lead_sponsor":"Nantes University Hospital","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • Sylvant (siltuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-04-06"}]